---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-008457"
form_type: "8-K"
ticker: "IMNN"
cik: "0000749647"
company_name: "Imunon, Inc."
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T02:52:03.104478+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Imunon reports FY2024 net loss $18.6M, OS benefit 13mo for IMNN-001, Phase 3 start Q1 2025

## Summary
- Net loss $18.6M ($1.62/share) in 2024 vs $19.5M in 2023; cash $5.9M at year-end, sufficient into late Q2 2025.
- OVATION 2: median OS 13 months (HR 0.69) with IMNN-001 + chemo vs SOC alone; >1/3 survived >36 months.
- Phase 3 pivotal trial of IMNN-001 to begin Q1 2025 after positive End-of-Phase 2 and CMC meetings with FDA.
- New CMO Douglas V. Faller, M.D., Ph.D. appointed Feb 18, 2025; leads clinical strategy for IMNN-001.
- PlaCCine vaccine Phase 1: IMNN-101 safe, induced 2-4x NAb titers; seeks partners for further development.

## SEC filing metadata
- accession: 0001493152-25-008457
- form_type: 8-K
- ticker: IMNN
- cik: 0000749647
- company_name: Imunon, Inc.
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/749647/000149315225008457/0001493152-25-008457-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/749647/000149315225008457/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-008457
- JSON: https://secwatch.observer/filing/0001493152-25-008457.json
- Plain text: https://secwatch.observer/filing/0001493152-25-008457.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.